Dr. Carlsson’s research is focused on screening and early detection of prostate cancer. She is an investigator in the world’s largest randomized study of screening for prostate cancer, the European Randomized Study of Screening for Prostate Cancer. Dr. Carlsson’s research aims at finding a better balance between the harms and benefits of prostate-specific antigen (PSA) screening, through the use of multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging. Her work, together with Dr. Vickers, on how the benefits and harms of prostate cancer screening varies by PSA levels at age 60 and how re-screening intervals can be adapted accordingly, was published in the British Medical Journal and has helped inform the screening guidelines in place at MSK as well as national guidelines in Sweden. Dr. Carlsson is particularly interested in implementation science and implementing established knowledge into routine clinical care, including educational efforts directed at physicians and patients.